MFS
ARQT icon

Mirabella Financial Services’s Arcutis Biotherapeutics ARQT Stock Holding History

Mirabella Financial Services’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-45,299
Closed -$9.85M – 486
2023
Q1 		$9.85M Buy
+45,299
New +$655K 1.49% 13
2020
Q4 		– Sell
-11,691
Closed -$343K – 316
2020
Q3 		$343K Buy
+11,691
New +$312K 0.05% 195

Other funds holding ARQT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Mirabella Financial Services's ARQT Position: Q2 2023 in Review

Mirabella Financial Services sold out of Arcutis Biotherapeutics (ARQT) in Q2 2023, closing a stake of 45,299 shares — an estimated $9.85M sold.

Mirabella Financial Services first reported a position in ARQT in Q3 2020 and held it in 2 quarters. The position peaked at $9.85M in Q1 2023. 136 funds tracked by Wall St. Rank hold ARQT as of Q2 2023.

  • Mirabella Financial Services reported no remaining Arcutis Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Mirabella Financial Services sold 45,299 Arcutis Biotherapeutics shares in Q2 2023, an estimated $9.85M.
  • Mirabella Financial Services first reported a position in Arcutis Biotherapeutics in Q3 2020 and held it in 2 quarters.
  • Mirabella Financial Services's Arcutis Biotherapeutics position peaked at $9.85M in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2023.

Based on Mirabella Financial Services's 13F filing for Q2 2023, filed 7 Aug 2023.